Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Antonio Giordano et al.|The Lancet Oncology|2019Cited by 193
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Fabiola Giudici et al.|JNCI Journal of the National Cancer Institute|2020Cited by 102
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Mario Giuliano et al.|Cancers|2021Cited by 35
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Daniele Generali, Sergio Venturini et al.|Cancer Treatment Reviews|2022Cited by 35
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Daniele Generali, Mario Giuliano et al.|Cancers|2021Cited by 19